Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients
Suttorp M, Metzler M, Shimada H, Bansal D, Gunes AM, Kalwak K, Sedlacek P, Baruchel A, Biondi A, Hijiya N, Schultz KR, Schrappe M, Millot F (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 65
Journal Issue: 12
DOI: 10.1002/pbc.27431
Abstract
Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.
Authors with CRIS profile
Markus Metzler
Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie
Involved external institutions
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Keio University / 慶應義塾大学
Japan (JP)
Postgraduate Institute of Medical Education and Research
India (IN)
Uludag University / Uludağ Üniversitesi
Turkey (TR)
Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu
Poland (PL)
Univerzita Karlova v Praze / Charles University in Prague
Czech Republic (CZ)
Robert Debré Hospital for Mothers and Children / Hôpital Robert Debré pour la mère et l'enfant
France (FR)
University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB
Italy (IT)
Northwestern University
United States (USA) (US)
BC Children's Hospital Research Institute
Canada (CA)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Centre hospitalier universitaire de Poitiers (CHU de Poitiers)
France (FR)
Germany (DE)
Keio University / 慶應義塾大学
Japan (JP)
Postgraduate Institute of Medical Education and Research
India (IN)
Uludag University / Uludağ Üniversitesi
Turkey (TR)
Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu
Poland (PL)
Univerzita Karlova v Praze / Charles University in Prague
Czech Republic (CZ)
Robert Debré Hospital for Mothers and Children / Hôpital Robert Debré pour la mère et l'enfant
France (FR)
University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB
Italy (IT)
Northwestern University
United States (USA) (US)
BC Children's Hospital Research Institute
Canada (CA)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Centre hospitalier universitaire de Poitiers (CHU de Poitiers)
France (FR)
How to cite
APA:
Suttorp, M., Metzler, M., Shimada, H., Bansal, D., Gunes, A.M., Kalwak, K.,... Millot, F. (2018). Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. Pediatric Blood & Cancer, 65(12). https://dx.doi.org/10.1002/pbc.27431
MLA:
Suttorp, Meinolf, et al. "Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients." Pediatric Blood & Cancer 65.12 (2018).
BibTeX: Download